Kaku Saito

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine · 2020 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Junji Tsurutani, Hiroji Iwata, Ian E. Krop et al. · Cancer Discovery · 2020 · 353 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

Kohei Shitara, Hiroji Iwata, Shunji Takahashi et al. · The Lancet Oncology · 2019 · 229 citations

Medicine, Oncology, Pharmacology +13

Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

Benjamin Chuah, Boon Cher Goh, Soo‐Chin Lee et al. · Cancer Science · 2010 · 143 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa et al. · Journal of Clinical Oncology · 2022 · 119 citations · Full text

Medicine, Oncology, Pharmacology +16